|

anti-CD19/BCMA U CAR T cells Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Changhai Hospital1

Indications

  • Primary Sjögren Syndrome1
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
  • Systemic Sclerosis1
  • Systemic Lupus Erythematosus1
  • Lupus1

Other1 trial

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.